PMID- 26199721
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150722
LR  - 20200930
IS  - 2045-1253 (Print)
IS  - 2045-1261 (Electronic)
IS  - 2045-1253 (Linking)
VI  - 5
IP  - 3
DP  - 2015 Jun
TI  - MDMA for the treatment of mood disorder: all talk no substance?
PG  - 179-88
LID - 10.1177/2045125315583786 [doi]
AB  - BACKGROUND: Unipolar depression is the third highest contributor to the global 
      burden of disease, yet current pharmacotherapies typically take about 6 weeks to 
      have an effect. A rapid-onset agent is an attractive prospect, not only to 
      alleviate symptoms before first-line antidepressants display therapeutic action, 
      but as a further treatment option in nonresponsive cases. It has been suggested 
      that 3,4-methylene-dioxymethamphetamine (MDMA) could play a part in the treatment 
      of depression, either as a rapid-onset pharmacological agent or as an adjunct to 
      psychotherapy. Whilst these hypotheses are in keeping with the monoamine theory 
      of depression and the principles surrounding psychotherapy, explicit experimental 
      evidence of an antidepressant effect of MDMA has rarely been established. AIMS: 
      To address the hypothesis surrounding MDMA as a rapid-onset antidepressant by 
      examining pharmacological, psychological and behavioural studies. We consider 
      whether this therapy could be safe by looking at the translation of neurotoxicity 
      data from animals to humans. METHOD: A literature review of the evidence 
      supporting this hypothesis was performed. CONCLUSIONS: The pharmacology of MDMA 
      offers a promising target as a rapid-onset agent and MDMA is currently being 
      investigated for use in psychotherapy in anxiety disorders; translation from 
      these studies for use in depression may be possible. However, experimental 
      evidence and safety analysis are insufficient to confirm or reject this theory at 
      present.
FAU - Patel, Rachel
AU  - Patel R
AD  - Green Templeton College, Woodstock Road, Oxford, OX2 6HG, UK.
FAU - Titheradge, Daniel
AU  - Titheradge D
AD  - St Hugh's College, Oxford, UK.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ther Adv Psychopharmacol
JT  - Therapeutic advances in psychopharmacology
JID - 101555693
PMC - PMC4502590
OTO - NOTNLM
OT  - MDMA
OT  - monoamine theory
OT  - mood disorder
OT  - psychotherapy
OT  - rapid-onset antidepressant
COIS- Conflict of interest statement: The authors declare no conflicts of interest in 
      preparing this article.
EDAT- 2015/07/23 06:00
MHDA- 2015/07/23 06:01
PMCR- 2015/06/01
CRDT- 2015/07/23 06:00
PHST- 2015/07/23 06:00 [entrez]
PHST- 2015/07/23 06:00 [pubmed]
PHST- 2015/07/23 06:01 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - 10.1177_2045125315583786 [pii]
AID - 10.1177/2045125315583786 [doi]
PST - ppublish
SO  - Ther Adv Psychopharmacol. 2015 Jun;5(3):179-88. doi: 10.1177/2045125315583786.